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Abstract
L-Glutamic acid, N,N-diacetic acid, tetrasodium salt (GLDA-Na4) (Kelforce
®) is sought to be used as a
zootechnical feed additive in chickens for fattening to improve the absorption of zinc from feed,
reducing zinc emissions through manure and thus, affecting favourably the environment. The product
has not been authorised in the European Union as a feed additive. Kelforce® is intended to be
marketed as a liquid and solid formulation, containing ≥ 47% and ≥ 30% of GLDA-Na4, respectively.
Kelforce® is safe for chickens for fattening at the maximum level of 1,000 mg GLDA-Na4/kg complete
feed. Based on the toxicological proﬁle of GLDA-Na4 and the consumer exposure to GLDA-Na4 and to
nitrilotriacetic acid trisodium salt (NTA-Na3; an impurity of the additive), the use of Kelforce
® at the
maximum proposed level in feed of chickens for fattening is of no concern for consumer safety. Due to
its low inhalation toxicity, the exposure to GLDA-Na4 is unlikely to pose a risk by inhalation. However,
owing to the high-dusting potential of the solid formulation, a risk from such high level of dust, even if
toxicologically inert, cannot be excluded. Kelforce® is not a skin/eye irritant or skin sensitiser. No risks
for the terrestrial compartment were identiﬁed at the maximum use level of the additive. Risks for the
aquatic compartment cannot be excluded based on the secondary effect of the additive on green
algae. In the absence of data, the Panel cannot conclude on the safety for the sediment compartment
or the possible ground water contamination. The risk of bioaccumulation and secondary poisoning
caused by the additive is considered very low. Owing to the inconsistent and conﬂicting results from
the studies assessed, the Panel on Additives and Products or Substances used in Animal Feed
(FEEDAP) cannot conclude on the efﬁcacy of the additive. The Panel made a recommendation
regarding the levels of formaldehyde and cyanide in the active substance.
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Summary
Following a request from the European Commission, the Panel on Additives and Products or
Substances used in Animal Feed (FEEDAP) was asked to deliver a scientiﬁc opinion on the safety and
efﬁcacy of Kelforce® (L-glutamic acid, N,N-diacetic acid, tetrasodium salt (GLDA-Na4)) as a feed additive
for chickens for fattening. This product has not been authorised in the European Union as a feed additive.
The additive is intended for use as a zootechnical additive (functional groups: substances which
favourably affect the environment and other zootechnical additives) in chickens for fattening. The
applicant suggests that it enhances the nutritional availability of dietary zinc in chickens for fattening,
by improving solubilisation or preventing precipitation in the gastrointestinal tract. Improving the
absorption of zinc from the feed would allow reducing the supplementation of zinc and consequently
decrease zinc emission through manure and would, if efﬁcacious, beneﬁt the environment.
The additive will be marketed in two formulations: solid and liquid, with a minimum speciﬁed
content of GLDA-Na4 of 30% and 47.4% (w/w), respectively; the remainder in the composition being
water. The applicant proposes a maximum use level of the active substance of 1,000 mg GLDA-Na4/kg
feed, equivalent to 2,110 mg/kg for the aqueous preparation and 3,333 mg/kg for the solid
formulation of the additive. Typical use ranges are reported to be 100–300 mg GLDA-Na4/kg feed for
the active substance, equivalent to 211–633 mg/kg for the liquid form and 333–1,000 mg/kg for the
solid form of the additive.
A tolerance study demonstrated that GLDA-Na4 was tolerated by chickens for fattening up to a
concentration of 3,000 mg/kg complete feed. The maximum recommended use level of 1,000 mg
GLDA-Na4/kg complete feed is therefore safe for chickens for fattening with a margin of safety of
about three.
In rats, GLDA-Na4 is poorly absorbed and is principally excreted as the intact molecule in the faeces,
while the limited amount of absorbed, GLDA-Na4 is eliminated unchanged through the urine. Limited
deposition in liver and muscle was observed in chickens fed up to 300 mg/kg feed, but no data were
collected from animals given the maximum proposed dose. The higher deposition of GLDA-Na4 in kidney
compared to liver and muscle probably reﬂects the renal pattern of excretion.
GLDA-Na4 did not induce any increase of gene mutations in the in vitro bacterial (Salmonella
Typhimurium) reverse and mammalian cell gen (hypoxanthine-guanine phosphoribosyltransferase
(HPRT) locus) tests. An in vitro chromosome aberration assay on the Chinese hamster lung (CHL) cell line
yielded equivocal results, but the outcome of the micronucleus assay in bone marrow of mice indicated
that GLDA-Na4 does not induce chromosome damage in vivo. Therefore, based on the weight of
evidence, the FEEDAP Panel concludes that GLDA-Na4 is non-genotoxic. High doses of NTA-Na3 induce
renal tumours in rodents; the available evidence indicates that this compound is not a gene mutagen or a
clastogen and that the tumorigenic effect occurs through a thresholded mechanism at high
concentrations.
The lowest no observed adverse effect level (NOAEL) found in animal studies with GLDA-Na4 was
20 mg/kg body weight (bw) per day, which corresponded to dose-related maternal gastrointestinal
complications in rabbits. An overall uncertainty factor of 100 is applied to derive an acceptable daily
intake (ADI) of 0.20 mg (200 lg) GLDA-Na4/kg bw.
The consumption of food from chickens fed Kelforce® at 10 times the highest inclusion level of
1,000 mg GLDA-Na4/kg complete feed would result in an exposure to GLDA-Na4 28-fold lower than the
ADI, and therefore, no concern for consumer safety is envisaged. No other hazards in the additive
represent a risk to the consumers.
Due to its low inhalation toxicity, the exposure to GLDA-Na4 in the additive is unlikely to pose a risk
by inhalation. However, the Panel notes that the solid formulation as described has an exceptionally
high-dusting potential and a risk from such a high level of dust, even if toxicologically inert, cannot be
excluded. Kelforce® has low dermal toxicity and it is not a skin or eye irritant or a skin sensitiser.
No risks for the terrestrial compartment were identiﬁed at the maximum use level of 1,000 mg
GLDA-Na4/kg complete feed. Risks for the aquatic compartment cannot be excluded based on the
secondary effect of the additive on green algae (reduction of nutrients). In the absence of data, the
FEEDAP Panel cannot conclude on the safety for the sediment compartment nor on the possible
contamination of the ground water. The risk of bioaccumulation and secondary poisoning caused by
the additive is considered very low.
The applicant provided six in vitro studies to support efﬁcacy,
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The applicant also submitted ﬁve short-term efﬁcacy studies
the FEEDAP Panel cannot
conclude on the efﬁcacy of the additive either as a Other zootechnical additive or as a Zootechnical
additive favourably affecting the environment.
The FEEDAP Panel recommended to set the levels of both formaldehyde and cyanide in the active
substance (aqueous solution of mg GLDA-Na4) at ≤ 10 mg/L.
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1. Introduction
1.1. Background and Terms of Reference
Regulation (EC) No 1831/20031 establishes the rules governing the Community authorisation of
additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any
person who seeking authorisation for a feed additive or for a new use of a feed additive shall submit an
application in accordance with Article 7.
The European Commission received a request from Selko B.V.2 for authorisation of the product
Kelforce®, L-glutamic acid, N,N-diacetic acid, tetrasodium salt (GLDA-Na4), when used as a feed additive
for chickens for fattening (category: zootechnical additives; functional groups: substances which
favourably affect the environment and other zootechnical additives).
According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the application
to the European Food Safety Authority (EFSA) as an application under Article 4(1) (authorisation of a
feed additive or new use of a feed additive). EFSA received directly from the applicant the technical
dossier in support of this application. The particulars and documents in support of the application were
considered valid by EFSA as of 29 November 2013.
According to Article 8 of Regulation (EC) No 1831/2003, EFSA, after verifying the particulars and
documents submitted by the applicant, shall undertake an assessment in order to determine whether
the feed additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on
the safety for the target animals, consumer, user and the environment and on the efﬁcacy of the
product Kelforce®, L-glutamic acid, N,N-diacetic acid, tetrasodium salt (GLDA-Na4), when used under
the proposed conditions of use (see Section 3.1.5).
1.2. Additional information
The additive Kelforce® contains GLDA-Na4. It is intended for use as a zootechnical additive
(functional groups: substances which favourably affect the environment and other zootechnical
additives) in chickens for fattening.
This product has not been authorised in the European Union as a feed additive. GLDA-Na4 is listed
under the European Commission Database on Cosmetic Ingredients as a chelating agent.3
2. Data and Methodologies
2.1. Data
The present assessment is based on data submitted by the applicant in the form of a technical
dossier4 in support of the authorisation request for the use of Kelforce®, GLDA-Na4, as a feed additive.
The technical dossier was prepared following the provisions of Article 7 of Regulation (EC) No 1831/2003,
Regulation (EC) No 429/20085 and the applicable EFSA guidance documents.
The Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) used the data
provided by the applicant together with data from other sources, such as peer-reviewed scientiﬁc
papers and other scientiﬁc reports to deliver the present output.
EFSA has veriﬁed the European Union Reference Laboratory (EURL) report as it relates to the
methods used for the control of the Kelforce®, GLDA-Na4, in animal feed. The Executive Summary of
the EURL report can be found in Annex A.6
1 Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in
animal nutrition. OJ L 268, 18.10.2003, p. 29.
2 Selko B.V. Jellinghausstraat 22, 5048 AZ Tilburg, The Netherlands
3 EU Cosmetic ingredient database. Available online: https://ec.europa.eu/growth/sectors/cosmetics/cosing_en
4 FEED dossier reference: FAD-2013-0022.
5 Commission Regulation (EC) No. 429/2008 on detailed rules for the implementation of Regulation (EC) No. 1831/2003 of the
European Parliament and of the Council as regards the preparation and the presentation of applications and the assessment
and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1.
6 The full report is available on the EURL website: https://ec.europa.eu/jrc/sites/default/files/FinRep-FAD-2013-0022-Kelforce-
corrected.pdf
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2.2. Methodologies
The approach followed by the FEEDAP Panel to assess the safety and the efﬁcacy of Kelforce®,
GLDA-Na4, is in line with the principles laid down in Regulation (EC) No 429/2008
7 and the relevant
guidance documents: Guidance on zootechnical additives (EFSA FEEDAP Panel, 2012a), Technical
guidance: Tolerance and efﬁcacy studies in target animals (EFSA FEEDAP Panel, 2011), Technical
Guidance for assessing the safety of feed additives for the environment (EFSA, 2008), Guidance for
establishing the safety of additives for the consumer (EFSA FEEDAP Panel, 2012b), Guidance on
studies concerning the safety of use of the additive for users/workers (EFSA FEEDAP Panel, 2012c).
3. Assessment
Kelforce® (GLDA-Na4) is intended to be used as a zootechnical feed additive in feed for chickens for
fattening. It is intended to enhance the nutritional availability of dietary zinc, by improving
solubilisation or preventing precipitation in the gastrointestinal tract. Improving the absorption of zinc
from the feed would allow reducing the supplementation of zinc and consequently decrease zinc
emission through manure, beneﬁting the environment.
3.1. Characterisation
3.1.1. Characterisation of the active substance
L-Glutamic acid, N,N-diacetic acid, tetrasodium salt (International Union of Pure and Applied
Chemistry (IUPAC) name: tetrasodium (2S)–2–[bis(carboxylatomethyl)amino]pentanedioate; Chemical
Abstracts Service (CAS) number: 51981–21–6; European Inventory of Existing Commercial Substances
(EINECS) number 257–573–7) has the molecular formula C9H9NO84Na and a molecular mass of
351.13. The structural formula is shown in Figure 1.
3.1.2. Characterisation of the additive
The additive is presented in two formulations: solid and liquid.
The liquid form of the additive has a minimum speciﬁed content of 47.4% (w/w) GLDA-Na4, the
remainder being water; this was conﬁrmed by the analysis of ﬁve batches (47.8–48.6% GLDA-Na4).
8 It
is a clear liquid with a slight ammonia odour and a density of 1,420 kg/m3.
The solid formulation has a minimum speciﬁed content of GLDA-Na4 of 30%, a maximum content
of silicic acid of 36% and 35% of water; the content of GLDA-Na4 was conﬁrmed by the analysis of
ﬁve batches (30.4–30.9% GLDA-Na4).
9 It is a white powder with a bulk density of 720 kg/m3.
Four batches of the liquid form of the additive were analysed for heavy metals (lead (Pb), cadmium
(Cd), mercury (Hg)) and arsenic (As), and all values were below the respective limit of detection (LOD)
(Pb ≤ 0.005 mg/kg; Cd ≤ 0.005 mg/kg; Hg < 0.01 mg/kg and As < 0.1 mg/kg).10 Levels of dioxins
Figure 1: Structural formula of L-glutamic acid, N,N-diacetic acid, tetrasodium salt
7 Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC)
No 1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications
and the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1.
8 Technical Dossier/Section II/Annex II_5.
9 Technical Dossier/Section II/Annex II_6.
10 Technical Dossier/Section II/Annex II_4.
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(0.09 ng WHO PCDD/F-TEQ/kg) and sum of dioxins and dioxins-like polychlorinated biphenyls (PCBs)
(0.125 ng WHO PCDD/F-PCB-TEQ/kg) were analysed in four batches of the liquid form.11 Five batches of
the solid form of the additive were analysed for heavy metals (Pb, Cd, Hg), ﬂuorine (F) and As,12 with
values often below the respective LOD (Pb ≤ 0.08 mg/kg, Cd ≤ 0.03 mg/kg, Hg < 0.01 mg/kg,
F ≤ 23 mg/kg and As ≤ 0.2 mg/kg).12 The same batches were analysed for dioxins (0.09 ng WHO PCDD/
F-TEQ/kg) and sum of dioxins and dioxins-like PCBs (0.116–0.179 ng WHO PCDD/F-PCB-TEQ/kg).13
Neither the additive nor the active substance has an speciﬁc entry in the Directive on Undesirable
substances in animal feed;14 however, a comparison of the levels of the impurities found in the additive
with those allowed in complete feed identiﬁed no concerns.
The product is regularly monitored for by-products or residues of raw materials and processing aids
that may be present in the aqueous solution of GLDA-Na4. The analysis of ﬁve batches showed that all
values (≤ 6 mg formaldehyde/L; ≤ 9 mg cyanide/L; ≤ 15 g sodium hydrochloride/L; ≤ 26 g GLDA-Na4
linear/L; ≤ 28 g GLDA-Na4 cyclic/L; ≤ 0.8 g nitrilotriacetic acid trisodium salt (NTA-Na3)/L; ≤ 50 mg
ammonia/L; ≤ 4 g sodium-glycolate /L; ≤ 7 g sodium-formate/L; ≤ 1 g iminodiacetic acid disodium salt/L)15
were below the speciﬁcations set by the applicant.16 Since both the liquid and solid formulations are
obtained from the starting aqueous solution of GLDA-Na4, the same purity criteria apply.
Particle size was determined in ﬁve batches of the solid additive by laser diffraction.17 The solid
formulation has a median particle size (v/v) of 105 lm, with 19.5% of the particles with a diameter
< 50 lm and 2.8% of the particles < 10 lm. The mean dusting potential determined in ﬁve batches of
the additive by the Stauber–Heubach method was 30.6 g/m3.18
3.1.3. Manufacturing process
3.1.4. Stability and homogeneity
The shelf-life of three batches of the aqueous solution was studied during storage in closed
containers at 20°C. Losses of GLDA-Na4 after 2 years were less than 0.4%.
19 Other ﬁve batches were
stored for 6 months at 40°C. No losses in GLDA-Na4 were observed.
The shelf-life of the solid formulation (three batches) was studied when stored for 24 months in
plastic bags at 25 or 40°C.20,21 Losses of GLDA-Na4 amounted to approximately 2% regardless of the
temperature.
The stability of the additive in premixtures and feed was studied only for the solid form; the results
obtained are also indicative of the stability of the liquid form. GLDA-Na4 was added at 1% in a
vitamin–mineral premix (containing choline chloride) for chickens for fattening (one batch) and stored
at room temperature (not speciﬁed) up to 6 months.20 Losses amounted to approximately 4% after
6 months.
The stability of GLDA-Na4 was monitored in one batch of feed for poultry, both in mash and
pelleted form.20 GLDA-Na4 was added at 100 mg/kg feed, and part of the feed was pelleted at
11 Technical Dossier/Section II/Annex II_12.
12 Technical Dossier/Section II/Annex II_13. Limits of Detection reported: arsenic, 0.10 mg/kg; cadmium, 0.01 mg/kg; ﬂuorine,
20 mg/kg, mercury 0.01 mg/kg; lead, 0.05 mg/kg.
13 Technical dossier/Section II/Annex II_14.
14 Directive 2002/32/EC of the European Parliament and of the Council of 7 May 2002 on undesirable substances in animal feed.
OJ L 140, 30.5.2002, p. 10.
15 Although melamine could be formed from cyanide and ammonia, given the amount of both impurities measured in the additive,
melamine will be orders of magnitude lower than the legal limit set for this substance in feed (2.5 mg/kg complete feed).
16 Speciﬁcations indicated in the technical dossier: formaldehyde < 50 mg/L; cyanide < 20 mg/L; free sodium hydrochloride
< 19 g/L; L-glutamic acid monoacetic acid sodium salt linear < 30 g/L; L-glutamic acid monoacetic acid sodium salt cyclic
< 30 g/L; nitrilotriacetic acid trisodium salt < 1 g/L; ammonia < 50 mg/L; Na-glycolate < 10 g/L; Na-formate < 10 g/L;
iminodiacetic acid disodium salt < 5 g/L.
17 Technical Dossier/Section II/Annex II_18.
18 Technical Dossier/Section II/Annex II_19.
19 Technical Dossier/Section II/Annex II_36.
20 Technical Dossier/Section II/Annex II_37.
21 Technical Dossier/Supplementary Information June 2014/Annex C.
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approximately 80°C. The pelleting process did not cause a decrease in the average content of GLDA-
Na4. No losses were observed either in mash or pelleted feed after 3 months of storage at room
temperature (not speciﬁed).
The capacity of the additive to homogeneously distribute in feed was studied in 10 subsamples of
the mash feed used in the stability study. The coefﬁcient of variation obtained was 6.1%. No data
were provided on the homogeneity of the liquid form of Kelforce® in feed, but in general, it might be
expected that a liquid additive distribute well in premixtures and complete feeds.
3.1.5. Conditions of use
Both forms of the additive are intended to be used in feed for chickens for fattening, added directly
in feed or via complementary feed or premixtures. The applicant proposes a maximum use level of the
active substance of 1,000 mg GLDA-Na4/kg feed, equivalent to 2,110 mg/kg for the aqueous
preparation and 3,333 mg/kg for the solid formulation of the additive. Typical use ranges are reported
to be 100–300 mg GLDA-Na4/kg feed for the active substance, equivalent to 211–633 mg/kg for the
liquid form and 333–1,000 mg/kg for the solid form of the additive.
3.2. Safety
3.2.1. Safety for the chickens for fattening
A total of 480 one-day-old male Ross 308 chickens were distributed to six treatments (8 replicates
of 10 birds per treatment).22 Maize–soybean meal basal diets (starter and grower) were supplemented
with the solid form of the additive to achieve a nominal content of GLDA-Na4 of 0, 100, 300, 1,000
(19), 3,000 (39) and 10,000 (109) mg/kg complete feed. The recovery of GLDA-Na4 was 87%, 94%,
95%, 92% and 89% in the starter and 91%, 95%, 91%, 92% and 98% in the grower diets. Diets in
pelleted form were fed for 35 days (day 0–10: starter diet; day 11–35 grower diet). A mineral and
vitamin premixture was applied across all the experimental diets, aiming to supply 100 mg zinc, 10 mg
copper, 100 mg manganese and 120 mg iron per kg diet. Regarding zinc, the analysed content in the
starter and grower diets was 96 and 85 mg/kg, respectively.23
General health of the animals was monitored daily. Body weight and feed intake per pen were
determined at 0, 10 and 35 days of age. Body weight gain and feed to gain ratio were calculated for
the different periods 0–10 days, 10–35 days and overall. Blood samples were obtained from three
birds per pen on day 35 for haematology and blood biochemistry.24 At the end of the experiment, one
bird per pen was selected for necropsy. In the necropsy, body and organ (liver and kidney) weights
were measured. Response parameters were subjected to the analysis of variance (ANOVA) according
to a completely randomised block design (pens blocked according to their position in the experimental
facility).
Overall mortality was on average 7.4% and not treatment related (Table 1). No signiﬁcant adverse
effects on feed intake and weight gain were observed up to a concentration of GLDA-Na4 of 3,000 mg/kg
feed. A signiﬁcant reduction in ﬁnal weight, weight gain and feed intake, with the increase in feed to gain
ratio was observed with the 10,000 mg/kg dose (Table 1).
22 Technical Dossier/Section III/Annexes Sect. III/Annex III-1.
23 The FEEDAP Panel notes that the analysed and expected zinc concentration in started and grower feed differs considerably
(the analysed levels being about 40 mg/kg complete feed lower than the expected).
24 White blood cells, red blood cells, haemoglobin, haematocrit, mean corpuscular volume, mean corpuscular haemoglobin
(MCH), differential leucocyte count, albumin, c-glutamyl transferase (GGT), aspartate aminotransferase (AST), alanine
aminotransferase (ALT), urea, total protein (TP), glucose, alkaline phosphatase (AP), lactate dehydrogenase (LDH), albumin/
globulin, creatinine, calcium, phosphorus, chlorine, total bilirubin, sodium and potassium) and levels of zinc, copper,
manganese and iron.
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A signiﬁcant increase in haemoglobin, haematocrit, erythrocyte and heterophil granulocyte counts
was observed in the 10,000 mg/kg group, compared to all the rest other treatments. An increase of
mean corpuscular haemoglobin was also observed at 3,000 mg/kg, but without a dose-dependent
relationship. Total protein, albumin and sodium were signiﬁcantly increased in the 10,000 mg/kg
group. Alkaline phosphatase was reduced and c-glutamyl transferase was increased in the 10,000 mg/
kg group compared with the control. The relative kidney weight of the 10,000 mg/kg group was also
signiﬁcantly increased compared with the control (from 0.68% to 0.79% of live weight).
3.2.1.1. Conclusions on safety for the target species
The study provided demonstrated that GLDA-Na4 was tolerated by chickens for fattening up to a
concentration of 3,000 mg/kg complete feed. The maximum recommended use level of 1,000 mg
GLDA-Na4/kg complete feed is therefore safe for chickens for fattening with a margin of safety of
about three. This would correspond to a maximum safe concentration of 2,110 mL liquid Kelforce®/kg
feed or 3,333 mg solid Kelforce®/kg feed.
3.2.2. Safety for the consumer
3.2.2.1. Absorption, distribution, metabolism, excretion (ADME) and residues
No studies on absorption, distribution, metabolism and excretion (ADME) in the target animals were
provided. The kinetics studies in rats give some information on absorption and excretion. Residue data
were obtained from the tolerance study with chickens for fattening.
3.2.2.1.1. Kinetics studies in rats
Excretion of GLDA-Na4 was studied using 48 Wistar rats of both sexes, receiving either a single oral
(gavage) or an intraperitoneal dose of the test item.25 Urine and faeces samples were taken before
dosing, and in the intervals: 0–24, 24–48 and 48–72 h after dosing. Samples were analysed for GLDA-Na4
by liquid chromatography–mass spectrometry (LC–MS). Four male and four female rats each were given
by gavage a single dose of 100, 300 or 1,000 mg GLDA-Na4/kg body weight (bw). More than 85% of
GLDA-Na4 was recovered intact in the faeces within 24 h and 93–99% after 72 h. The remaining fraction
(0.9–7.3%) was detected in the urine. Total recoveries of GLDA-Na4 from the faeces and urine over the
72-h period ranged from 96% to 103%.
The other 24 rats (four rats of each sex per dose) received an intraperitoneal injection of 5, 15 or
50 mg GLDA-Na4/kg bw, representing 5% of the oral doses. In 20 of these 24 rats, GLDA-Na4 was
excreted mainly in urine (66–100% of total excretion), whereas only in the other four rats, GLDA-Na4
excretion in faeces was greater than that in urine. The percentages of faecal or urinary GLDA-Na4
excretion were not dose related. The total GLDA-Na4 recovery ranged between 75% and 103%.
Overall, this experiment indicates that (a) GLDA-Na4 is poorly absorbed (< 5% of the oral dose)
and mostly excreted unchanged, and (b) of the limited amount of GLDA-Na4 absorbed on average
> 85% is excreted within 24 h via urine/faeces, with an overall recovery of 75–103% reported after
72 h.
The low urinary excretion of GLDA-Na4 was conﬁrmed in a subchronic repeated-dose 90-day oral
toxicity study (Section 3.2.2.2.2) with Wistar rats using the same GLDA oral doses as above.26
Table 1: Feed intake, ﬁnal body weight, feed to gain ratio and mortality in the tolerance study
GLDA-Na4
(mg/kg feed)
Total Feed intake
(g/bird)
Final body weight (g) Feed to gain Mortality (%)
0 3,304ab 2,338b 1.44bc 11.2
100 3,339ab 2,348b 1.45c 3.7
300 3,420a 2,439a 1.43ab 8.9
1000 3,316ab 2,377ab 1.42a 7.6
3000 3,289b 2,374ab 1.41a 7.5
10000 2,961c 2,044c 1.48d 5.3
a,b,c,d: Values in a column with a different superscript are signiﬁcantly different (p < 0.05)
25 Technical Dossier/Supplementary Information June 2014/Annex A.
26 Technical Dossier/Section III/Reference 3.2.01
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3.2.2.1.2. Residue study in chickens for fattening
At the end of the 35-day tolerance study with chickens for fattening (described in Section 3.2.1),
birds fed diets with 100, 300 or 10,000 mg GLDA-Na4/kg were randomly selected (one bird per pen,
n = 8 per dose level) and samples of breast muscle, kidney and liver were collected from each animal
for analysis of GLDA-Na4 and NTA-Na3 residues.
27 The concentrations in feed corresponded to the
proposed normal inclusion levels of 100–300 mg/kg and 10-fold the proposed maximum inclusion
level. GLDA-Na4 and NTA were analysed in tissue extracts using LC–MS.
28
NTA-Na3 is an impurity that may be present in GLDA-Na4 containing products and was detected in
the analytical data provided for ﬁve batches of Kelforce® with a mean value of 0.48 g/L additive
(Section 3.1.2)
The concentrations of GLDA-Na4 were higher in kidney than in liver or muscle, that showed
comparable concentrations at 100 or 300 mg/kg; a sharp increase of residues was observed at the
10-fold overdosing (Table 2). The concentration of NTA was found to be below the limit of
quantiﬁcation (LOQ) (0.06 mg/kg) in all tested tissues. No data are available on the residue deposition
of GLDA-Na4 in fat and skin; the FEEDAP Panel considers that given the high water solubility of this
compound (at least 65,000 mg/L; see Table 3), deposition in skin and fat is expected to be low.
3.2.2.1.3. Conclusions
In rats, GLDA-Na4 is poorly absorbed and is principally excreted as the intact molecule in the
faeces, while the limited amount of absorbed GLDA-Na4 is eliminated unchanged through the urine.
Limited deposition in liver and muscle was observed in chickens fed up to 300 mg/kg feed, but no data
were collected from animals given the maximum proposed dose. The higher deposition of GLDA-Na4 in
kidney compared to liver and muscle probably reﬂects the renal pattern of excretion.
3.2.2.2. Toxicological studies
3.2.2.2.1. Genotoxicity studies
The test substance used in the four genotoxicity studies was a preparation containing 71% GLDA-Na4.
GLDA-Na4 was tested in Salmonella Typhimurium strains TA1535, TA1537, TA1538, TA98 and TA100
by the Ames plate incorporation method at ﬁve dose levels, in triplicate, both with and without the
addition of a rat liver homogenate metabolising system (S9 mix).29 Two independent experiments were
performed up to a maximum concentration of 5,000 lg/plate in compliance with the Organisation for
Economic Cooperation and Development (OECD) Guideline No 471 (version 1983). No signiﬁcant
increase in the numbers of revertant colonies was recorded for any of the bacterial strains with any
dose of the test item, either with or without metabolic activation, while positive control chemicals
produced marked increases in the number of revertant colonies.
Table 2: Concentration of GLDA-Na4 in edible tissues from chickens for fattening
Tissue GLDA-Na4 inclusion level in feed (mg/kg) Tissue GLDA-Na4 concentration (mg/kg)
Breast meat 100 0.008  0.003
300 0.021  0.008
10,000 0.378  0.102
Liver 100 0.010  0.002
300 0.018  0.004
10,000 1.35  0.012
Kidney 100 0.100  0.019
300 0.131  0.018
10,000 3.99  0.37
27 NTA-Na3 is an impurity that may be present in GLDA-Na4 containing products and was detected in the analytical data provided
for ﬁve batches of Kelforce® with a mean value of 0.48 g/L additive (Section 3.1.2). It is also a compound of toxicological
concern (see Section 3.2.2.2.1).
28 Technical Dossier/Supplementary Information June 2014/Annex B.
29 Technical Dossier/Section III/References Sect. III/Ref 3.2.09.
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The potential mutagenicity of GLDA-Na4 was tested on the hypoxanthine-guanine phosphoribosyl-
transferase (HPRT) locus of Chinese hamster ovary cells in the presence and absence of an S9
metabolic activation system, in compliance with the OECD Guidelines No. 476 (version 1984).30 The
cells were treated with the test material at ﬁve dose levels, in duplicate, up to a maximum
concentration of 3,650 lg/mL, corresponding to 10 mM. The entire experiment was repeated to
conﬁrm the result. No signiﬁcant increases in mutant frequency were observed at any dose level of the
test substance, either with or without metabolic activation, in either the ﬁrst or second experiment.
Signiﬁcant increases in the mutant frequency were observed in the positive controls, indicating the
satisfactory performance of the test and of the metabolising system.
The potential of GLDA-Na4 to induce chromosomal aberrations was tested on the metaphase
chromosomes of the CHL cell line, according to the OECD Guidleline 473.31 The test material was
evaluated at dose levels of 456.25, 912.5, 1,825 and 3,650 lg/mL. In Experiment 1, cells were harvested
at a single time point (12 h), both with and without metabolic activation (S9 mix). In Experiment 2, six
treatment regimens were used: 6 h exposure both with and without S9 mix followed by 18 h treatment-
free incubation; 4 h exposure with the addition S9 mix followed by 8 h treatment-free incubation; 12 h
continuous exposure; 24 h continuous exposure and 48 h continuous exposure without S9 (top exposure
tested 1,825 lg/mL). The test material induced no concentration-related or statistically signiﬁcant
increases in the frequency of cells with aberrations in Experiment 1, whereas two positive control
materials (mitomycin-C (MMC) and cyclophosphamide (CP)) induced signiﬁcant increases of aberrations
as expected. In Experiment 2, small, but statistically signiﬁcant, increases in the frequency of cells with
aberrations were observed at the highest concentration tested (3,650 lg/mL) in the 6-h exposure group,
both with and without S9 activation; both positive controls (MMC and CP) performed as expected. For the
12 h continuous exposure group, there were no concentration-related or statistically signiﬁcant increases
in the number of cell with aberrations, while positive controls (MMC and CP) responded as expected. No
effect was evident for the 24 h continuous exposure group at any concentration tested, with the positive
control (MMC) behaving as expected. On the other hand, in the 48-h continuous exposure group, a small
but statistically signiﬁcant increase in the numbers of cells with aberrations was found at the highest
concentration tested (1,825 lg/mL); in this treatment, cells were exposed only without S-9 and there
was no corresponding positive control. All of the increases in aberrant cell frequency seen in this study
were small and restricted to the maximum dose levels at which some cytotoxicity was observed. Indeed,
3,650 lg/mL (top concentration tested in the 6 h and 12 h groups) corresponds to 10 mM, usually
considered the limit concentration that should not be exceeded in genotoxicity studies, because an
osmotic effect can affect the integrity of cell membranes. Overall, the results of this study should be
considered as positive but only at a limit concentration for osmotic effects; therefore, its biological
relevance is questionable.
A micronucleus test in mice was performed in compliance with the OECD Guideline No 474 (version
1981).32 Groups of 10 mice (ﬁve males and ﬁve females) received the test substance via the
intraperitoneal route at 100, 200 and 400 mg/kg bw; further groups were given the vehicle alone or
cyclophosphamide (positive control), respectively. Animals from all treatments were killed at 24 h post
dosing. Additionally, four groups of 10 mice (ﬁve males and ﬁve females) received the top dose
(400 mg/kg bw) or the vehicle only and were killed at 48 or 72 h post dosing, respectively. The bone
marrow from all animals was examined. Polychromatic erythrocyte (PCE) and normochromatic
erythrocyte (NCE) were scored for the presence of micronuclei. Two female rats died at the top dose
level in the 72-h group. Increased activity, decreased respiratory rate, laboured respiration and ataxia
were seen in the 400 mg/kg treated group. Only increased activity was observed in the 200 mg/kg
group and no clinical signs were observed in the 100 mg/kg group. No signiﬁcant change in the
PCE/NCE ratio was observed after any treatment. There was a small but statistically signiﬁcant increase
in the incidence of micronucleated PCE in mice dosed with 400 mg/kg of the test item in the 72-h
harvest group when compared to the concurrent vehicle control group. The positive control group
showed a signiﬁcant increase in the incidence of micronucleated PCE, hence conﬁrming the sensitivity of
the system. The FEEDAP Panel notes that, albeit the PCE/NCE ratio was unchanged, the use of the
intraperitoneal route and the dose-related induction of systemic toxicity support the systemic exposure
to the test item. The FEEDAP Panel considers that the slight, albeit signiﬁcant, increase of micronuclei
observed only at 400 mg/kg bw in the 72 h group was accompanied by overt toxicity including
30 Technical Dossier/Section III/References Sect. III/Ref 3.2.10.
31 Technical Dossier/Section III/References Sect. III/Ref 3.2.11.
32 Technical Dossier/Section III/References Sect. III/Ref 3.2.12.
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treatment-related mortality. The OECD guideline 474 (Mammalian erythrocyte micronucleus test, 2014)
indicates that relevant effects should be detected at exposure levels not exceeding the maximum
tolerated dose, i.e. in the presence of some toxicity, but with no mortality or overt distress. Thus, the
slight increase of micronuclei observed at the top dose level in the 72 h group is likely related to general
toxicity. Accordingly, the test item was considered to be non-genotoxic in vivo under the conditions of
the test.
Information on nitrilotriacetic acid trisodium salt genotoxicity
NTA-Na3 is an impurity that may be present in GLDA-Na4 containing products and was detected in the
analytical data provided for ﬁve batches of Kelforce® with a mean value of 0.48 g/L additive
(Section 3.1.2). NTA-Na3 is classiﬁed by the International Agency for Research on Cancer (IARC) as
possibly carcinogenic to humans based on the consistent induction of renal tumours in rodent
carcinogenicity studies (class 2B). According to the evaluation of the IARC, NTA acid and its disodium and
trisodium salts were not genotoxic in mammalian cells in vitro, were not mutagenic to bacteria and were
negative in experimental systems in vivo, except for the induction of aneuploidy in mouse germ cells (IARC,
1999). Aneuploidy, in the absence of DNA reactivity (that should result also in gene mutation and/or
chromosome breakage), is assumed to origin from interference with the protein of the mitotic spindle and
as such to occur through a thresholded mechanism only at rather high concentrations. The study of
Nesslany et al. (2008) showed also in vivo and in vitro clastogenic activity in mammalian cells but
attributed these effects to a consequence of the chelating properties of the substance that induce calcium
deprivation, cytotoxicity and eventually clastogenicity as a secondary effect. This mechanism of
genotoxicity is considered to have a threshold.
Conclusions on genotoxicity
GLDA-Na4 did not induce any increase of gene mutations in the in vitro bacterial (Salmonella
Typhimurium) reverse and mammalian cell gen (HPRT locus) tests. An in vitro chromosome aberration
assay on the CHL cell line yielded equivocal results, but the outcome of the micronucleus assay in
bone marrow of mice indicated that GLDA-Na4 does not induce chromosome damage in vivo.
Therefore, based on the weight of evidence, the FEEDAP Panel concludes that GLDA-Na4 is non-
genotoxic.
High doses of NTA-Na3 induce renal tumours in rodents. The available evidence indicates that this
compound is not a gene mutagen or a clastogen and that the tumorigenic effect occurs through a
thresholded mechanism at high concentrations.
3.2.2.2.2. Subchronic repeated-dose oral toxicity study
The applicant provided a subchronic repeated-dose 90-day oral toxicity study with GLDA-Na4
(95  1%) given by daily gavage (OECD Guideline 408) to Wistar rats.33 One control group and three
treated groups (100, 300 and 1,000 mg GLDA-Na4/kg bw per day) were tested, each consisting of 10
males and 10 females. An extra 10 animals per sex in the control and high-dose group were allowed
to additional 14 days of observation, after the removal of test item on day 90.
Doses up to 1,000 mg GLDA-Na4/kg bw per day caused no treatment-related changes in clinical
appearance, functional observations, body weight and food consumption.
A number of signiﬁcant changes (from the pairwise comparison with the control values) were
observed at the highest dose of GLDA-Na4 (1,000 mg/kg bw per day) in some of the haematological
parameters: increased red blood cell counts in males, reduced mean corpuscular volume and mean
corpuscular haemoglobin in both sexes, increased red cell distribution width and platelet counts in
females. The only effect observed at 300 mg/kg bw per day was a reduced mean corpuscular
haemoglobin in both sexes. Changes in clinical biochemistry parameters at 1,000 mg/kg bw per day at
the end of the 90-day treatment included increased albumin and cholesterol levels, and reduced
creatinine, inorganic phosphate and chloride levels in males and/or females. These changes were
reversible as they were absent at the end of the 14-day observation period.
A number of changes were detected in the urinalysis values at 1,000 mg/kg bw per day, which
included an increased sodium concentration/excretion in both sexes, and a reduced urinary volume
with increased speciﬁc gravity, protein level and potassium concentration in females. In males, the
increase in sodium concentration/excretion in urine was also observed at 300 mg/kg bw per day.
33 Technical Dossier/Section III/References Sect. III/Ref 3.2.14.
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These changes were absent at the end of the 14-day observation period, indicating that these were
reversible in nature.
At the end of the 90-day treatment phase, there was an increase in absolute and relative kidney
weight in males exposed to GLDA-Na4 at 1,000 mg/kg bw per day. However, there was no
histopathological evidence of an effect on kidneys. At the end of the 14-day observation period, kidney
weights were similar in treated and control groups. In females treated with 1,000 mg GLDA-Na4/kg per
day, there was no effect on kidney size, but absolute and relative kidney weight was increased at the end
of the observation period. No alterations were observed in organs and tissues other than kidney.
In summary, at 300 mg/kg bw per day, GLDA-Na4 reduced mean corpuscular haemoglobin level
and increased urinary sodium concentration/excretion. At 1,000 mg/kg bw per day, a range of more
pronounced changes in blood and urine were noted, with increased kidney weight. Although no
histopathological alterations were observed and most effects were reversible, the FEEDAP
Panel considers that the observed changes are dose related and have a potential toxicological
relevance; therefore, the FEEDAP Panel identiﬁes a no observed adverse effect level (NOAEL) for
GLDA-Na4 of 100 mg/kg bw per day.
3.2.2.2.3. Reproduction toxicity studies (including prenatal developmental toxicity)
Study 1
A two-generation toxicity study of GLDA-Na4 was conducted in rats exposed through the diet
following OECD Guideline 416.34
The F0-generation included ﬁve groups of 24 male and 24 female Wistar Han rats exposed to
GLDA-Na4 (91.0  0.5%) at dose levels of 0 (group 1), 1,500 (group 2), 5,000 (group 3) or
15,000 mg/kg feed (groups 4 and 5). Groups 2–4 were exposed to GLDA-Na4 included into a pelleted
diet (total content of zinc: 88.6–93.5 mg per kg diet). Group 5 animals received a pelleted diet with
GLDA-Na4 at the high-dose level, supplemented with 1,000 mg zinc carbonate/kg (total concentration
of zinc: 605–609 mg per kg diet). The additional dietary zinc in Group 5 was included in the
experiment to compensate for possible (reproduction) toxic effects, if any, due to the chelating
properties of GLDA-Na4. Rats from the control group (Group 1) received the same pelleted diet as
those from groups 2–4 but without GLDA-Na4. F0-males and F0-females were exposed to GLDA-Na4
from 10 weeks prior to mating and exposure was continued until euthanasia (males) or one day before
euthanasia (females). Males were killed as soon as possible after the delivery of the litters. F0-females
were allowed to produce and rear a litter until day 21 of lactation and then killed (on day 21 post-
partum or shortly thereafter). On day 4 of lactation, litters were reduced in size to eight pups (four of
each sex when possible) by random culling. After weaning, one F1-male and one F1-female of each
litter of groups 1–4 were selected for mating with offspring of another litter of the same dose group to
produce a F2-generation.
The F1-generation included four groups of 24 males and 24 females Wistar Han rats exposed to
GLDA-Na4 at dose levels of 0, 1,500, 5,000 or 15,000 mg/kg feed. GLDA-Na4 was included into a
pelleted diet (total content of zinc: 83.8 mg per kg diet). No additional zinc-supplemented group was
added in this phase of the study. Rats from the control group received the same pelleted diet but
without GLDA-Na4. After weaning, animals were treated for a minimum of 70 days prior to mating and
continued until euthanasia (males) or 1 day before euthanasia (females). Males were killed as soon as
possible after the delivery of the litters. F1-females were allowed to produce and rear a litter until day
21 of lactation and then killed (on day 21 post-partum or shortly thereafter). On day 4 of lactation,
litters were reduced in size to eight pups by random culling.
All animals were subjected to daily clinical observation. Body weight and food consumption were
measured over the treatment period. Blood samples were collected for analysis from F0-females with live
offspring. At necropsy, urine samples were collected and macroscopic observations and organ weights
were recorded. Reproduction parameters and breeding data were assessed. In addition, one male and
one female per litter of the F1-pups selected for culling were examined for possible skeletal variations or
malformations (excluding ossiﬁcation). No other developmental toxicity parameters were recorded.
No unscheduled deaths occurred during the trial. No treatment-related clinical signs were observed
and no adverse effects on body weight, body weight gain, food consumption, haematology, clinical
biochemistry and urinalysis parameters, macroscopy or organ weights were noted following treatment
with GLDA-Na4 up to 15,000 mg/kg with or without zinc added. At 15,000 mg/kg without or with zinc
34 Technical Dossier/Section III/References Sect. III/Ref 3.2.15.
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(groups 4 and 5, respectively), increased mean kidney weight (absolute and relative to body weight)
was observed in F0- and F1-adults. Histopathological renal changes were observed in F1-adults,
consisting in increased cortical tubular dilation in females and increased corticomedullary tubular
basophilia in males. No adverse effects were identiﬁed in dose levels 1,500 and 5,000 mg/kg in all
generations.
It was concluded that the parental NOAEL was 5,000 mg/kg feed, which is equal to 287–389 mg
and 380–894 mg GLDA-Na4 per kg bw per day for males and females, respectively.
Reproduction parameters (mating performance, number of implantation sites, duration of gestation
and fertility parameters), breeding parameters (dead and living pups at ﬁrst litter check, postnatal loss,
living pups on day 4 post-partum and viability index) and skeletal variations or malformations were not
affected up to a dose level of 15,000 mg/kg GLDA-Na4 with or without zinc added. Based on the tested
reproductive parameters, the dosage level of 15,000 mg/kg GLDA-Na4 was considered as the NOAEL for
reproductive toxicity, corresponding to at least 908 (males) and 1230 (females) mg GLDA-Na4 per kg bw
per day. However, based on renal ﬁndings in F0 and F1 adults, the overall NOAEL was 5,000 mg/kg feed,
corresponding to at least 287 (males) and 380 (females) mg GLDA-Na4 per kg bw per day.
Study 2
A developmental toxicity study with rabbits following OECD Guideline 414 was performed.35 Eighty-
eight mated female New Zealand white (NZW) rabbits were assigned to four dose groups each
containing 22 animals. GLDA-Na4 (87.3  0.5%) was administered once daily by gavage from days
7–28 post-coitum at doses of 20 (Group 2), 75 (Group 3) and 300 mg/kg bw (Group 4). Rabbits of the
control group (Group 1) were given water without GLDA-Na4.
No treatment-related mortality occurred during the study. Maternal toxicity was noted at 300 mg/kg
bw per day, with clinical signs such as an increased incidence of dark faeces, diarrhoea and reduced
faeces output. Food and water consumption were reduced. In addition, body weight gain was decreased,
with several animals showing a transient body weight loss. However, there were no statistically signiﬁcant
changes in (absolute) body weight or body weight gain corrected for uterus in any of the groups. In
animals receiving 75 mg/kg bw per day, dark faeces, diarrhoea, reduced faeces production and slightly
reduced food and water intake were also observed.
No signiﬁcant differences were observed between control and treated groups regarding number of
corpora lutea, implantation sites, viable or dead foetuses, early or late resorptions, or pre- and post-
implantation loss. No developmental toxicity (viscera and skeleton) was observed.
The maternal NOAEL was identiﬁed as 20 mg/kg bw per day and the developmental NOAEL was
300 mg/kg bw per day.
3.2.2.3. Derivation of health-based guidance value
The FEEDAP Panel concludes that Kelforce® is non-genotoxic.
The lowest NOAEL found in animal studies with GLDA-Na4 was 20 mg/kg bw per day, which
corresponded to dose-related maternal gastrointestinal complications in rabbits. An overall uncertainty
factor of 100 is applied to derive an acceptable daily intake (ADI) of 0.20 mg (200 lg) GLDA-Na4/kg bw.
3.2.2.4. Assessment of consumer safety
The exposure to GLDA-Na4 of consumers of products derived from animals receiving the additive
was derived using the theoretical daily human consumption of tissues from birds of the standard food
basket indicated in Regulation (EC) No 429/2008 (300 g of breast meat, 100 g of liver and 10 g of
kidney) and the residues of GLDA-Na4 (mean value plus 2 9 standard deviation, reﬂecting the 95th
percentile) detected in the study in chickens for fattening (Section 3.2.2.1.2). No data on the residues
at the highest recommended dose (1,000 mg GLDA-Na4/kg complete feed was made available);
therefore, the data from animals receiving 10 times the highest inclusion level were considered. The
calculation gave a theoretical intake of GLDA-Na4 from food of animal origin of 7 lg/kg bw per day in
a 60-kg adult which is only 3.5% of the ADI (200 lg GLDA-Na4/kg bw). The consumption of food from
chickens fed Kelforce® at 10 times the highest inclusion level of 1,000 mg GLDA-Na4/kg complete feed
would result in an exposure to GLDA-Na4 28-fold lower than the ADI.
NTA-Na3 is present in low concentrations in the additive but could not be quantiﬁed in tissues of
chickens for fattening (LOQ 0.06 mg/kg) after exposure to the 10-fold of the highest applied feed
concentration of the additive. Exposure of the consumers by ingesting 500 g animal products from
35 Technical Dossier/Section III/References Sect. III/Ref 3.2.17.
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treated birds would therefore not exceed 0.03 mg/person per day, assuming that all animal products
contained NTA-Na3 at LOQ concentration. Thus, the FEEDAP Panel considers that this impurity is not
likely to pose a safety concern for the consumer.
3.2.2.5. Conclusions on safety for the consumer
No concern for consumer safety is envisaged. No other hazards in the additive represent a risk to
the consumers.
3.2.3. Safety for the user
3.2.3.1. Effects on respiratory system
Because of the percentage of inhalable and respirable particles (19.5% of < 50 lm diameter and
2.8% of < 10 lm diameter)36 and the substantial dusting potential of 30.6 g/m3 of the additive,37 the
applicant submitted an inhalation study with GLDA-Na4.
An acute inhalation study38 was performed in accordance with OECD Guideline 403. Five male and
ﬁve female Wistar rats were exposed nose-only to an intended concentration of 5 g GLDA-Na4/m
3 for
4 h (aerosol from GLDA-Na4 90  1%) with a measured exposure concentration of 4.2 g GLDA-Na4/m3.
Observed clinical signs (i.e. slight bradypnea during exposure and a soiled fur of the head, neck, back
and/or abdomen shortly after exposure) were no longer evident on day 2. Snifﬁng was noticed in four
animals shortly after exposure, in seven animals on day 1 and in one animal on day 2. A discharge from
the eyes was seen in one animal on day 1. No other abnormalities were noted during the 14-day
observation period. The limited and transient non-lethal effects observed in this study show that
GLDA-Na4 has low inhalation toxicity potential.
The dry form of the additive contains silicic acid as carrier. Measurements performed by X-ray
diffraction on three batches of the additive, each analysed in triplicate, conﬁrmed that crystalline silica
(quartz) was not detected in the respirable dust.39,40
Due to its low inhalation toxicity, the exposure to GLDA-Na4 in the additive is unlikely to pose a risk
by inhalation. However, the Panel notes that the solid formulation as described has an exceptionally
high dusting potential (30.6 g/m3) and a risk from such a high level of dust, even if toxicologically
inert, cannot be excluded. The occupational exposure limits for inert dust in the European Union (EU)
Member States are 10 mg/m3 for inhalable dust and 3–4 mg/m3 for respirable dust.41
3.2.3.2. Effects on eyes and skin
3.2.3.2.1. Acute dermal toxicity
The acute dermal toxicity of GLDA-Na4 (91.0  0.5%) was evaluated in a study following OECD
Guideline 402.42 No mortality occurred and body weight gain during the observation period was within
the range expected for rats of this strain and age. The macroscopic examination during necropsy showed
no signiﬁcant gross changes. Flat and/or hunched posture, piloerection and/or chromodacryorrhoea were
observed in all animals from day 1 up to and including day 4. Slight scales and/or scabs were seen in the
treated skin area of four females from day 3 up to and including day 9. Based on the results, the additive
is considered to have a low dermal toxicity.
3.2.3.2.2. Skin irritation/corrosion
Irritancy potential of GLDA-Na4 was assessed following one OECD Guideline 404 study.
43 A very slight
erythema in the treated skin of two animals after 1 h was observed. All skin sites appeared normal after
24 h. The observations of the study showed that GLDA-Na4 was not irritant to rabbit skin.
44
36 Technical Dossier/Section III/Annexes Sect. III/Annex III_3.
37 Technical Dossier/Section III/Annexes Sect. III/Annex III_4.
38 Technical Dossier/Section III/References Sect. III/Ref 3.3.01.
39 Technical Dossier/Supplementary Information July 2017/Annex S-1.
40 Technical Dossier/Supplementary Information July 2017/Annex S-2.
41 https://www.eurosil.eu/sites/eurosil.eu/ﬁles/ﬁles/OEL-FULL-TABLE-Oct07-Europe.pdf; http://limitvalue.ifa.dguv.de/WebForm_gw2.
aspx
42 Technical Dossier/Section III/References Sect. III/Ref 3.3.03.
43 Technical Dossier/Section III/References Sect. III/Ref 3.3.04.
44 Technical Dossier/Section III/References Sect. III/Ref 3.3.05.
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3.2.3.2.3. Eye irritation
The irritancy potential of GLDA-Na4 was assessed following one OECD Guideline 405 study.
45,44 No
corneal or iridial effects were observed. Minimal conjunctival irritation was noted in all treated eyes 1 h
after treatment and persisted in one treated eye at the 24-h observation. All treated eyes appeared
normal 48 h after treatment. Based on the results of the study, GLDA-Na4 is not considered as an eye
irritant.
3.2.3.2.4. Skin sensitisation
The sensitisation potential of GLDA-Na4 (74.33%) was assessed in a Magnusson & Kligman
maximisation test, following OECD Guideline 406.46 None of the guinea pigs exposed to GLDA-Na4
showed positive skin responses. GLDA-Na4 is not considered as a skin sensitiser.
3.2.3.2.5. Silicic acid
Silica is not regarded as a substance of concern regarding dermal toxicity, skin and eye irritation
and skin sensitisation (EFSA, 2004).
3.2.3.3. Conclusions on safety for the user
Due to its low inhalation toxicity, the exposure to GLDA-Na4 in the additive is unlikely to pose a risk
by inhalation. However, the Panel notes that the solid formulation as described has an exceptionally
high-dusting potential and a risk from such a high level of dust, even if toxicologically inert, cannot be
excluded.
Kelforce® has low dermal toxicity. It is not a skin or eye irritant or a skin sensitiser.
3.2.4. Safety for the environment
The active substance is not a physiological/natural substance of established safety for the
environment. Consequently, according to Regulation (EC) No 429/2008, the Phase I assessment is
required to determine the predicted environmental concentration (PEC).
Initially, a total residues approach is employed in Phase I and II of the assessment, meaning that
the PEC is calculated based on the assumption that all the additives are excreted and that 100%
remains as the parent compound.
3.2.4.1. Phase I Assessment
3.2.4.1.1. Physico-chemical properties of the additive
The physico-chemical properties of GLDA-Na4 are summarised in Table 3.
Table 3: Physico-chemical properties of GLDA-Na4
Property Value Unit
Molecular mass 351.13 Da
Dissociation constant pKa(a)
(Values determined at 25°C with an ionic strength of 0.1 molar)
2.56/3.49/5.03/9.26(b) –
Water solubility(21°C)(c) At least 65,000 mg/L
Vapour pressure (20°C)(d) 80 Pa
Koc: organic carbon–water partition coefﬁcient
(e) < 32 L/kg
Kow: octanol/water partition coefﬁcient
(f) Log Kow < 0
(a): Technical Dossier/Section II/Annex II_22.
(b): Considering the four ionisation steps.
(c): Technical Dossier/Section II/Annex II_24.
(d): Technical Dossier/Section II/Annex II_25.
(e): Technical Dossier/Section II/Annex_II_27.
(f): Technical Dossier/Section III/Annex II_26.
45 Technical Dossier/Section III/References Sect. III/Ref 3.3.06.
46 Technical Dossier/Section III/References Sect. III/Ref 3.3.07.
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3.2.4.1.2. Fate and behaviour
Fate in soil: Adsorption
The applicant provided information on the adsorption potential of the GLDA-Na4. The provided Koc
value < 32 L/kg (value estimated by high-performance liquid chromatography (HPLC), following the
OECD Guideline 121) represents the average measured KOC value for GLDA-Na4 in the ionised form
(pH = 2) as well as in the non-ionised form (pH = 7).
Fate in soil/Biodegradation
The applicant did not provide data on degradation of the substance in soil. The applicant provided
results on biodegradability from the closed bottle test (OECD Guideline 301D). In all experiments, the
biodegradation percentage was between 72% and 83% at day 28, showing that GLDA-Na4 is readily
biodegradable in freshwater under aerobic conditions. A further prolonged closed bottle biodegradation
test in seawater showed 7% biodegradation at day 14, 72% at day 28 and 83% at day 60.
Conclusion on fate and behaviour
The average measured KOC value for GLDA-Na4 is < 32 L/kg; therefore, the value used in the
environmental assessment was 32 L/kg. The tested substance was found to be readily biodegradable
in aquatic compartment. It is very unlikely that GLDA-Na4 would persist and accumulate in soil. The
value of DT50 of 28 days was used in the Phase I PEC calculation, as a surrogate for the DT50 in soil.
The value of Koc used in the assessment (32 L/kg) indicates that GLDA-Na4 will be mobile in soil.
3.2.4.1.3. Predicted environmental concentrations (PECs)
The PECs in soil (PECsoil), ground water (PECgw) and surface water (PECsw) were calculated
according to EFSA FEEDAP Guidance (EFSA, 2008). At the proposed maximum use level of 1,000 mg/kg
complete feed, the threshold values for soil and groundwater were exceeded (Table 4);47 therefore, a
Phase II environmental risk assessment is required.
3.2.4.2. Phase II Assessment
3.2.4.2.1. Predicted environmental concentrations (PECs)
Reﬁnement based on metabolism
GLDA-Na4 is almost completely excreted from chickens for fattening as the parent compound;
therefore, no reﬁnement of PEC based on the metabolism of GLDA-Na4 is possible.
Reﬁnement based on degradation in manure
No data were submitted on the possible degradation of GLDA-Na4 in manure. The applicant,
however, provided information on degradation of GLDA-Na4 in anaerobic conditions using digested
sludge following OECD Guideline 311.48 Results did not show any biodegradation (0% over 60 days),
and therefore, GLDA-Na4 can be regarded as not biodegradable under anaerobic conditions, such as
those in manure.
3.2.4.2.2. PECs calculation in Phase II
The applicant did not provide data on soil degradability; thus, more sophisticated environmental
exposure models cannot be used to determine PECgw and PECsw. Due to a lack of metabolism of
GLDA-Na4 in animals, the PEC values used in the exposure assessment are those indicated in Table 5.
Table 4: Initial PEC in soil, ground water and surface water at the inclusion level of 1,000 mg
GLDA-Na4 per kg feed of chickens for fattening
Inclusion
level (mg/kg)
PEC in soil
(lg/kg)
PEC in ground
water (lg/L)(a)
PEC in surface
water (lg/L)
1,000 5,194 7,612 2,537
(a): The surrogate for the PEC groundwater in the Phase I is pore water.
47 Technical Dossier/Supplementary Information November 2015.
48 Technical Dossier/Section III/References Sect. III/Ref 3.4.08.
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3.2.4.2.3. Effect assessment
Ecotoxicity studies
Terrestrial compartment – Toxicity to microorganisms
In the 28-day soil microorganism test (OECD 216), GLDA-Na4 (minimum 47%) was incorporated
into the soil at geometric mean measured concentrations of 6.40, 10.7, 21.9, 43.1 and 90.3 mg GLDA-
Na4/kg soil dry weight (DW), respectively. A group with untreated soil was included as control.
Concentrations of nitrate were measured in soil samples of each treatment at day 0 and following
incubation for 7, 14 and 28 days. Nitrate formation rates were calculated from the difference in
concentrations measured at each sampling occasion and those originally present on day 0 and
compared to that of an untreated control.
No inhibition of the rate of nitrate formation was observed at any time point up to the highest
GLDA-Na4 concentration tested, 90.3 mg/kg soil DW. Indeed, GLDA-Na4 addition to soil dose
dependently increased the rate of nitrate formation (60% stimulation at 90.3 mg/kg soil DW). This
concentration is 17-fold higher than the PECsoil resulting from the maximum GLDA-Na4 inclusion level
and it is considered that GLDA-Na4 in Kelforce
® has no negative long-term impact on nitrogen
transformation in soil (EFSA, 2008).
An activated sludge respiration inhibition test following OECD Guideline 209 was performed to
evaluate the effects of GLDA-Na4 in the environment and in biological wastewater treatment plants.
49
The toxicity to activated sludge was determined by measuring the respiration rate after a contact
period of 30 minutes at various concentrations of GLDA-Na4 (25.75 mg/L, 51.5 mg/L, 103 mg/L,
206 mg/L and 412 mg/L). Controls were measured at the beginning and at the end of the test. No
inhibition of the respiration was measured at a concentration of 412 mg GLDA-Na4/L, the highest
concentration tested. Although activated sludge is not a compartment of relevance for the
environmental fate of Kelforce® when used in chickens feed, the study does provide some further
evidence of a high tolerance of microorganisms to GLDA-Na4.
Terrestrial compartment – Terrestrial plants, growth test
A terrestrial plants, growth test (OECD 208) was carried out on GLDA-Na4 (minimum 47%). The
test item was incorporated into soil at measured concentrations of 1.72, 3.33, 11, 43, 130 and
754 mg/kg DW, and seeds of one monocotyledon (oats, Poaceae), and two dicotyledons (rape,
Brassicaceae; soybean, Leguminosae) were sown. Seeds sown in untreated soil served as control.
Nitrate concentrations were measured in soil samples of each treatment at days 0, 7, 14 and 28.
Nitrate formation rates were calculated from the difference in concentrations measured at each
sampling occasion and those originally present on day 0 and compared to that of an untreated control.
No effects were observed in the terrestrial plants up to the highest concentration of GLDA-Na4
tested, 754 mg/kg soil DW. Thus, the no observed effect concentration (NOEC) is ≥ 754 mg/kg soil DW.
Terrestrial compartment – Earthworm reproduction test
The OECD 222 Earthworm reproduction test was conducted using measured GLDA-Na4
concentrations of 3.74, 9.39, 15.4, 38.0 and 248 mg/kg soil DW, administered to artiﬁcial soil
containing 10% peat. No effects on adult earthworms were observed after exposure for 28 days. After
another 28 days, the mean number of juveniles produced per replicate was 109 in the control and
ranged from 92 to 162 in the test item treatments. There was no statistically signiﬁcant reduction of
reproduction compared to the control. Since no effects were observed at the highest concentration of
GLDA-Na4 tested, 248 mg/kg soil DW, this was considered the NOEC value.
Table 5: Initial PEC in soil, ground water, surface water and sediment at the inclusion level of
1,000 mg GLDA-Na4 per kg feed of chickens for fattening
Inclusion level
(mg/kg)
PEC in
soil (lg/kg)
PEC in ground
water (lg/L)(a)
PEC in surface
water (lg/L)
PEC sediment
(mg/kg)
1,000 5,194 7,612 2,537 8,120
(a): The surrogate for the PEC groundwater in the Phase I is pore water.
49 Technical Dossier/Section III/References Sect. III/Ref 3.4.09.
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Freshwater compartment – Toxicity to aquatic algae
The effect of GLDA-Na4 on the growth of the green algae Scenedesmus subspicatus was evaluated
following OECD Guideline 201.50 S. subspicatus was exposed to an aqueous solution of GLDA-Na4 for
72 h and 24  1°C, under constant illumination and agitation. The results of the initial range-ﬁnding
study in the standard OECD growth medium showed that GLDA-Na4 has no effect on growth at the
test concentrations of 0.10 and 1.0 mg/L; however, signiﬁcant inhibition of growth was observed at 10
and 100 mg/L. The applicant considered that the effect on growth of algae was due to chelating of
nutrients caused by test substance. The range-ﬁnding test on modiﬁed micronutrients resulted in the
NOEC of 10 mg/GLDA-Na4, while the use of the modiﬁed macronutrient growth medium resulted in the
NOEC of 100 mg/L. The range-ﬁnding test in a non-modiﬁed culture medium resulted in an ErC50
> 1 mg/L and a NOEC value of 1 mg GLDA-Na4/L.
Freshwater compartment – Short-term toxicity to aquatic invertebrates
Acute toxicity of GLDA-Na4 was tested in a 48-h acute immobilisation study
51 with Daphnia magna
under static conditions and following OECD Guideline 202. Tested concentrations were 0 (control, 2
replicates) and 100 mg/L (4 replicates). No behavioural abnormalities and no immobility were
observed during this limit test and the 48-h EC50 is therefore > 100 mg/L.
Freshwater compartment – Long-term toxicity to aquatic invertebrates
Chronic toxicity of GLDA-Na4 on the reproductive efﬁcacy of Daphnia magna was evaluated in a
semistatic test following OECD Guideline 211.52 D. magna was exposed to different GLDA-Na4
concentrations (control, 0.5, 13.5, 36.5, 98.4 and 265.7 mg/L, 10 replicates each) for 21 days. Toxicity
criterion was the reproductive capacity expressed as the number of neonates per daphnid per day.
Immobilisation of parent daphnids was tested during at least 6 days/week by gently shaking the test
vessel. Living and dead neonates per brood or abortions were monitored and any abnormal observation
recorded. No effects were observed on reproduction and parental length, and the NOEC is therefore
≥ 265.7 mg GLDA-Na4/L, the highest concentration tested. There was likewise no effect at any
concentration on immobilisation and the EC50 for parent survival was hence > 265.7 mg GLDA-Na4/L.
Freshwater compartment – Short-term toxicity in ﬁsh
Acute toxicity of GLDA-Na4 in rainbow trout (Oncorhynchus mykiss) was evaluated following a
protocol in line with OECD Guideline 203.53 Rainbow trout (three groups of 10 ﬁsh, 20 L tanks) were
exposed to GLDA-Na4 at a limit concentration of 100 mg/L (one control group and two replicates) for a
period of 96 h. Mortalities were recorded at 3, 6, 24, 48, 72 and 96 h. No mortality was found in any
of the replicates at any time point. A 96-h LC50 could not be established but was higher than the limit
concentration of 100 mg GLDA-Na4/L.
Short-term effects of GLDA-Na4 to the embryo and sac fry stages of zebraﬁsh (Danio rerio) were
evaluated following OECD Guideline 212.54 Eggs of zebraﬁsh were exposed at different nominal
concentrations of GLDA-Na4 (control, 21.3, 47.0, 103, 227 and 500 mg/L) in a ﬂow-through exposure
design for 9 days. The highest concentration of GLDA-Na4 tested (500 mg/L) increased the pH of the
water to 9.93 (mean) compared with 7.65 (mean) in the control. Therefore, a second 500 mg/L
exposure group was included in which the pH was adjusted to 7.67 (average). Measured
concentrations of GLDA-Na4 were 96–119% of the nominal in all groups throughout exposure. The
following endpoints were evaluated: egg hatch, time to hatch, fry growth (expressed as length and
weight), morphological and behavioural effects, post hatch survival, overall fry survival and mortality,
respectively.
In the 500 mg/L group at pH 9.93, mortality was 100%. However, mortality was likely aggravated
by the high pH because in the pH-adjusted group at the same concentration, mortality was lower
(30%) and not statistically signiﬁcantly elevated (one-way ANOVA with Dunnett’s test, p > 0.05,
n = 3). In the second highest concentration (227 mg/L), average mortality was 27% and this was also
not statistically different from the overall average. Thus, the cumulative overall mortality was not
increased in any of the groups where pH was maintained below 9 and the LC50 was > 500 mg/L.
Hatching was the most sensitive endpoint with a NOEC of 103 mg/L.
50 Technical Dossier/Section III/References Sect. III/Ref 3.4.10.
51 Technical Dossier/Section III/References Sect. III/Ref 3.4.11.
52 Technical Dossier/Section III/References Sect. III/Ref 3.4.12.
53 Technical Dossier/Section III/References Sect. III/Ref 3.4.13.
54 Technical Dossier/Section III/References Sect. III/Ref 3.4.14.
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Conclusion on effect assessment for the soil, aquatic and sediment compartments
No inhibition of the rate of nitrate formation was observed at any time point up to the highest
GLDA-Na4 concentration tested, 90.3 mg/kg soil DW, leading to the conclusion that tested substance
has no negative impact on nitrate formation in soil. No effects were observed in the terrestrial plants
growth test up to the highest concentration of GLDA-Na4 tested, 754 mg/kg soil DW. Thus, the NOEC
is ≥ 754 mg/kg soil DW. In the earthworm reproduction test, no effects were observed at the highest
tested concentration of 248 mg GLDA-Na4 per kg of soil DW. This value was considered the NOEC for
earthworm reproduction.
The NOEC for green algae in the modiﬁed macronutrient test estimated to be 100 mg GLDA-Na4/L was
selected for the assessment of risk in the aquatic compartment. However, the NOEC of 1 mg GLDA-Na4/L
from the range-ﬁnding test in a non-modiﬁed culture medium is also considered in the environmental risk
assessment of GLDA-Na4, since the reduction of nutrients may be considered a detrimental effect to the
environment, in the absence of further information which may address the problem in a more realistic
way. It was also noted that the temperature during the test (24  1°C) was at the limit of acceptable
temperature regimes for this test. The 48-h test of acute toxicity of GLDA-Na4 led to the conclusion that
EC50 for D. magna is > 100 mg/L. The reproductive effect of GLDA-Na4 on D. magna was estimated as
the highest tested concentrations resulting in no effect – NOEC of ≥ 265.7 mg GLDA-Na4/L. Acute toxicity
on ﬁsh was not observed at concentrations ≥ 100 mg GLDA-Na4/L.
The applicant did not provide any data for the assessment of the risk for the sediment
compartment.
3.2.4.2.4. Risk characterisation (PEC/PNEC ratio)
The risk characterisation ratios for terrestrial, freshwater and sediment compartments are reported
in Tables 6, 7 and 8, respectively.
Since the ratio PEC/PNEC is lower than 1, no risk is expected for terrestrial compartment.
Table 6: Risk characterisation (PEC/PNEC ratio) for terrestrial compartment
Taxa PECsoil (lg/kg) NOEC (mg/kg) AF PNEC (lg/kg) PEC/PNEC
Earthworm 5,194 248 10 24,800 0.2
Plants 754 10 75,400 0.6
AF: assessment factor; PNEC: predicted no effect concentration.
Table 7: Risk characterisation (PEC/PNEC ratio) for freshwater compartment
Taxa
PECsw
(lg/L)
E(L,r)C50/NOEC
(mg/L)
AF
PNEC
(lg/L)
PEC/PNEC
Algae 2,537 > 100 50 2,000(a)
20(b)
1.27(a)
126.8(b)Selenastrum subspicatus 100(a)
1(b)
Aquatic invertebrates
Daphnia magna acute > 100
Daphnia magna reproduction 265.7(c)
Fish 103
Brachydanio rerio
AF: assessment factor; PNEC: predicted no effect concentration.
(a): NOEC for algae in the macronutrient-modiﬁed growth medium.
(b): NOEC for algae in the OECD standard non-modiﬁed culture medium.
(c): NOEC for daphnids.
Table 8: Risk characterisation (PEC/PNEC ratio) for sediment
Taxa
PECsediment
(lg/kg)
NOEC
(mg/kg)
AF
PNEC
(lg/kg)
PEC/PNEC
Sediment-dwelling invertebrates
Chironomus riparius
8,120 / / / /
AF: assessment factor; PNEC: predicted no effect concentration.
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Risks for the aquatic compartment cannot be excluded, mainly due to the secondary effect of the
additive on green algae (reduction of nutrients).
Risk of bioaccumulation and secondary poisoning
GLDA-Na4 is a non-lipophilic compound. The Log of partitioning coefﬁcient between octanol/water
(Log KOW) is below 0. Thus, the risk of bioaccumulation and secondary poisoning caused by this
compound is considered very low.
Silicic acid
Silicic acid is ubiquitous in the environment, being a natural component of soil, sediments and living
organisms. As such, its safety for the environment needs no further consideration.
3.2.4.3. Conclusions on safety for the environment
No risks for the terrestrial compartment were identiﬁed at the maximum use level of 1000 mg
GLDA-Na4/kg complete feed.
Risks for the aquatic compartment cannot be excluded based on the secondary effect of the
additive on green algae (reduction of nutrients).
In the absence of data, the FEEDAP Panel cannot conclude on the safety for the sediment
compartment nor on the possible contamination of the ground water.
The risk of bioaccumulation and secondary poisoning caused by the additive is considered very low.
3.3. Efﬁcacy for chickens for fattening
In its scientiﬁc opinion on the potential reduction of the currently authorised maximum zinc content
in complete feed, the FEEDAP Panel proposed a reduction of the total zinc content in feed for chickens
for fattening to 100 mg Zn/kg feed (EFSA FEEDAP Panel, 2014). The Commission reacted to this
Opinion by reducing the maximum total zinc contents in feed for chickens for fattening from 150 mg/kg
diet (Regulation (EC) No 1334/2003)55 to 120 mg/kg diet (Commission Implementing Regulation (EU)
2016/1095).56
The applicant proposes that Kelforce® (47% of GLDA-Na4) enhances the nutritional availability of
the zinc of the diets for chickens for fattening, by improving solubilisation or preventing precipitation in
the gastrointestinal tract. Improving the absorption of zinc from the feed would allow reducing the
supplementation of zinc and consequently decrease zinc emission through manure and would if
efﬁcacious, beneﬁt the environment. To assess the increase of zinc bioavailability, bone zinc is the
preferred marker. In addition, balance studies are suggested in order to assess total retention of zinc
and the reduction of zinc excretion (EFSA FEEDAP Panel, 2011). According to the National Research
Council (NRC), diets with 40 mg Zn/kg complete feed are recommended to meet zinc requirements of
chicken for fattening (NRC, 1994; see also EFSA FEEDAP Panel, 2014).
3.3.1. In vitro studies
Six in vitro studies were submitted
55 Commission Regulation (EC) No 1334/2003 of 25 July 2003 amending the conditions for authorisation of a number of
additives in feedingstuffs belonging to the group of trace elements. OJ L 187, 26.7.2003, p. 11.
56 Commission Implementing Regulation (EU) 2016/1095 of 6 July 2016 concerning the authorisation of Zinc acetate dihydrate,
Zinc chloride anhydrous, Zinc oxide, Zinc sulphate heptahydrate, Zinc sulphate monohydrate, Zinc chelate of amino acids
hydrate, Zinc chelate of protein hydrolysates, Zinc chelate of glycine hydrate (solid) and Zinc chelate of glycine hydrate (liquid)
as feed additives for all animal species and amending Regulations (EC) No 1334/2003, (EC) No 479/2006, (EU) No 335/2010
and Implementing Regulations (EU) No 991/2012 and (EU) No 636/2013. OJ L 182, 7.7.2016, p. 7.
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3.3.2. In vivo short-term studies
A total of ﬁve efﬁcacy short-term studies were provided by the applicant to demonstrate that the
additive may improve the nutritional availability of zinc in chickens for fattening.
3.3.2.1. Study 1
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3.3.2.2. Study 2
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3.3.2.3. Study 3
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3.3.2.4. Study 4
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3.3.2.5. Study 5
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3.3.2.6. Conclusions on efﬁcacy
Therefore, the FEEDAP Panel cannot conclude on the efﬁcacy of the additive either as an Other
zootechnical additive or as a Zootechnical additive favourably affecting the environment.
3.4. Post-market monitoring
The FEEDAP Panel considers that there is no need for speciﬁc requirements for a post-market
monitoring plan other than those established in the Feed Hygiene Regulation64 and Good
Manufacturing Practice.
4. Conclusions
The additive is safe for chickens for fattening when used at the maximum proposed level of
1,000 mg GLDA-Na4/kg complete feed; this is equivalent to 2,110 mg liquid Kelforce
®/kg feed or
3,333 mg solid Kelforce®/kg feed.
The FEEDAP Panel concludes that the use of Kelforce® as feed additive at the maximum proposed
level of 1,000 mg GLDA-Na4/kg complete feed of chickens for fattening is of no concern for consumer
safety.
Due to its low inhalation toxicity, the exposure to GLDA-Na4 in the additive is unlikely to pose a risk
by inhalation. However, the Panel notes that the solid formulation as described has an exceptionally
high-dusting potential and a risk from such a high level of dust, even if toxicologically inert, cannot be
excluded. Kelforce® is not a skin and eye irritant or a skin sensitiser.
No risks for the terrestrial compartment were identiﬁed at the maximum use level of 1,000 mg
GLDA-Na4/kg complete feed. Risks for the aquatic compartment cannot be excluded based on the
secondary effect of the additive on green algae (reduction of nutrients). In the absence of data, the
FEEDAP Panel cannot conclude on the safety for the sediment compartment or the possible
contamination of the ground water. The risk of bioaccumulation and secondary poisoning caused by
the additive is considered very low.
Owing to the inconsistencies and conﬂicting results from the studies assessed, the FEEDAP
Panel cannot conclude on the efﬁcacy of the additive.
5. Recommendations
The speciﬁcations for the content of formaldehyde and cyanide in the active substance (aqueous
solution of mg GLDA-Na4) should be adjusted to reﬂect the analytical values; the FEEDAP
Panel recommends to set both levels at ≤ 10 mg/L.
Documentation provided to EFSA
1) Kelforce®. L-glutamic acid, N,N-diacetic acid, tetrasodium salt (GLDA-Na4) in the form of an
aqueous solution of GLDA-Na4 and GLDA-Na4
. May 2013. Submitted by Selko B.V.
64 Regulation (EC) No 183/2005 of the European Parliament and of the Council of 12 January 2005 laying down requirements for
feed hygiene. OJ L 35, 8.2.2005, p. 1.
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2) Kelforce®. L-glutamic acid, N,N-diacetic acid, tetrasodium salt (GLDA-Na4) in the form of an
aqueous solution of GLDA-Na4 and GLDA-Na4
. Supplementary information June 2014. Submitted by Selko B.V.
3) Kelforce®. L-glutamic acid, N,N-diacetic acid, tetrasodium salt (GLDA-Na4) in the form of an
aqueous solution of GLDA-Na4 and GLDA-Na4
. Supplementary information November 2015. Submitted by Selko B.V.
4) Kelforce®. L-glutamic acid, N,N-diacetic acid, tetrasodium salt (GLDA-Na4) in the form of an
aqueous solution of GLDA-Na4 and GLDA-Na4
. Supplementary information July 2017. Submitted by Selko B.V.
5) Evaluation report of the European Union Reference Laboratory for Feed Additives on the
Methods(s) of Analysis for Kelforce®.
6) Comments from Member States.
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Abbreviations
ADI acceptable daily intake
ADME absorption, distribution, metabolism and excretion
AF assessment Factor
ANOVA analysis of variance
bw body weight
CAS Chemical Abstracts Service
CHL Chinese hamster lung
DW dry weight
DT50 half-life
EINECS European Inventory of Existing Commercial Substances
EURL European Union Reference Laboratory
FEEDAP EFSA Panel on Additives and Products or Substances used in Animal Feed
GLDA L-glutamic acid, N,N-diacetic acid
GLDA-Na4 L-glutamic acid, N,N-diacetic acid, tetrasodium salt
HPLC high-performance liquid chromatography
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HPRT hypoxanthine-guanine phosphoribosyltransferase
IARC International Agency for Research on Cancer
IUPAC International Union of Pure and Applied Chemistry
Koc organic carbon–water partition coefﬁcient
Kow octanol/water partition coefﬁcient
LC–MS liquid chromatography–mass spectrometry
LOD limit of detection
LOQ limit of quantiﬁcation
MMC mitomycin-C
NCE normochromatic erythrocytes
NOAEL no observed adverse effect level
NOEC no observed effect concentration
NRC National Research Council
NTA nitrilotriacetic acid
NTA-Na3 nitrilotriacetic acid trisodium salt
NZW New Zealand white
OECD Organisation for Economic Cooperation and Development
PCBs polychlorinated biphenyls
PCDDs polychlorinated dibenzo-para-dioxins
PCE polychromatic erythrocytes
PEC predicted environmental concentration
PNEC predicted no effect concentration
TEQ toxic equivalent factor
TP total protein
WHO World Health Organization
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Annex A – Executive Summary of the Evaluation Report of the European
Union Reference Laboratory for feed additives on the method(s) of
analysis for Kelforce®
In the current application authorisation is sought under article 4(1) for Kelforce (GLDA-Na4), for the
category/functional 4(c)(d) “zootechnical additives”/”substances which favourably affect the
environment”/”other zootechnical additives” according to the classiﬁcation system of Annex I of
Regulation (EC) No 1831/2003. Speciﬁcally, authorisation is sought for the use of the feed additive for
chicken for fattening. Kelforce active substance is L-glutamic acid N,N-diacetic acid tetrasodium salt
(GLDA-Na4). The product is intended to be marketed in a liquid form, containing at least 47.4% of
GLDA-Na4 and less than 50% water (GLDA-Na4 L) and in a solid form containing minimum 30% of
GLDA-Na4 and maximum 36% silicic acid and 35% water (GLDA-Na4 P).
The feed additive is intended to be included into premixtures and/or feedingstuffs with a maximum
feed additive content of 2110 or 3333 mg/kg feedingstuffs for the liquid or solid preparation,
respectively.
For the determination of GLDA-Na4 in the feed additive and premixtures, the Applicant submitted
an in-house validated and further veriﬁed method based on Reversed Phase High Performance Liquid
Chromatography coupled to spectrophotometric detection (RP-HPLC-UV), while for the determination
of GLDA-Na4 in the feedingstuffs the Applicant submitted an in-house validated and further veriﬁed
method based on Reversed Phase High Performance Liquid Chromatography coupled to mass
spectrometry detection (RP-HPLC-MS). The experimental evidence provided, allows the EURL to
recommend for ofﬁcial control the RP-HPLC-UV method for the determination of GLDA-Na4 in the feed
additive and premixtures and the RP-HPLC-MS method for the determination of GLDA-Na4 in
feedingstuffs
Further testing or validation of the methods to be performed through the consortium of National
Reference Laboratories as speciﬁed by Article 10 (Commission Regulation (EC) No 378/2005) is not
considered necessary.
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